{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:389850c403f2757e33de95a32631226fc9da5cbfecf27e99c27ce42f766f9747", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOTTNjZnNqRkdfaThrcWxsUmZQb2g5N3p2ek5YQThfM0lGRHlFYUVZMHBzOHoxQkM5R2E3QkY1RHVlSXU4WmlMTFd3OWxRNzJVa1RmbGFyLV9oc3o2NmtLcEN6LWhkS20zWFBPeHBHUV9weDdhZU14cktEeU5DTE81SERjbkFIb09pSUpyX0h4SkxzMXlsM1BxYm8tdjZIUHZseEM1TzhBcC1xd29hWkxKWWdkSXlOZGk3c3RScWd4NjhCQnRvenhkQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOTTNjZnNqRkdfaThrcWxsUmZQb2g5N3p2ek5YQThfM0lGRHlFYUVZMHBzOHoxQkM5R2E3QkY1RHVlSXU4WmlMTFd3OWxRNzJVa1RmbGFyLV9oc3o2NmtLcEN6LWhkS20zWFBPeHBHUV9weDdhZU14cktEeU5DTE81SERjbkFIb09pSUpyX0h4SkxzMXlsM1BxYm8tdjZIUHZseEM1TzhBcC1xd29hWkxKWWdkSXlOZGk3c3RScWd4NjhCQnRvenhkQQ?oc=5", "title": "Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore", "content_text": "Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore", "date_published": "2026-08-14T14:41:41+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:6f3ad19d45a6717c24f32fbbfc13925fbc5ddd56cad0c94e00daaf0deab9b172", "url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "title": "Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Amgen has returned 116.3% over the past five years, which puts more weight on whether the current valuation still leaves room for an attractive long term outcome. Plans to open a", "date_published": "2026-08-14T12:09:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AMGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc", "sentiment_url": "https://sharemaestro.com/sentiment/350e2440-2381-4144-857c-f6e37633f654/"}]}}, {"id": "source:feb4c10773207b089470a45f64ed6c862c294f24a43dcb044c603c039d23c4d0", "url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "external_url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "title": "Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains", "content_text": "While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading", "date_published": "2026-08-14T12:00:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}]}}, {"id": "source:5965bab414293756232d024d36146d3247dbbdcadb0cb3071528fa9a52f92949", "url": "https://www.biospace.com/fda/bms-welcomes-new-multiple-myeloma-drug-as-generics-batter-current-portfolio", "external_url": "https://www.biospace.com/fda/bms-welcomes-new-multiple-myeloma-drug-as-generics-batter-current-portfolio", "title": "BMS welcomes new multiple myeloma drug as generics batter current portfolio", "content_text": "Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, providing a crucial boost while BMS continues to manage the erosion of its older portfolio. This approval highlights BMS's CELMoD platform's potential, with another candidate currently under FDA review.", "date_published": "2026-08-14T11:41:23+00:00", "authors": [{"name": "BioSpace"}], "tags": ["Deals and strategy", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:4a3743dd6463ed105ffc9c1441902f440c6c025c3c9d0aedf7bd19fa086ad557", "url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "title": "Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing", "date_published": "2026-08-14T11:12:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc", "sentiment_url": "https://sharemaestro.com/sentiment/350e2440-2381-4144-857c-f6e37633f654/"}]}}, {"id": "source:69e41aa7e75f9ccc512ce8857abc35f4bdc160d3f676e2ad563cd137b39f126e", "url": "https://www.marketbeat.com/instant-alerts/filing-thomasville-national-bank-buys-shares-of-26575-abbvie-inc-abbv-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-thomasville-national-bank-buys-shares-of-26575-abbvie-inc-abbv-2026-08-14", "title": "Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV", "content_text": "Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a \"Moderate Buy\" consensus and an average price target of $275.50, and recently exceeded quarterly earnings and revenue estimates. The company also offers a quarterly dividend of $1.73 per share, representing a 2.8% yield.", "date_published": "2026-08-14T10:24:05+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc", "sentiment_url": "https://sharemaestro.com/sentiment/9a54a5f7-3445-44e1-a263-af644888772e/"}]}}, {"id": "source:0186585343a46a7d7d34fbc051bc32f552d01c8bd10d0bf5b491585b410abce5", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVDk0czRzV0JoaTZfT1k4dXVsQ1R4Z1RpZEg3TUVoWmpWN3ZpVDZSdlpwRjV1a091SEVFYnpRWFBXcTJPSUYxUHo4R0NGRVJyMlJmbm9XOWFjNVc1d3JJSjNmVWtZTTFxbUhXRDhsRU94bzB1blN1SGRCc0FsSXJCVUhndGFxRV9JR1U5WXZOcDlvMGlpaGFXQzRoMkpZYWM0SUo3SXU0c2FFaG1Ea2Z1OXk2TjhHemFL?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVDk0czRzV0JoaTZfT1k4dXVsQ1R4Z1RpZEg3TUVoWmpWN3ZpVDZSdlpwRjV1a091SEVFYnpRWFBXcTJPSUYxUHo4R0NGRVJyMlJmbm9XOWFjNVc1d3JJSjNmVWtZTTFxbUhXRDhsRU94bzB1blN1SGRCc0FsSXJCVUhndGFxRV9JR1U5WXZOcDlvMGlpaGFXQzRoMkpZYWM0SUo3SXU0c2FFaG1Ea2Z1OXk2TjhHemFL?oc=5", "title": "Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO", "content_text": "Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:19:38+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:112c5c0806e0952f7c4ad658563007404406e8007b16bb9ad0bb0233353a85c7", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNbUxaVGpOTU5oZFZxeXc2OVRUNEhMdElKNmJ1V2YyNWY0RVVqNWk5LTRhVVpBekNjMVl0R01QZG5kNDdId1FvWW5xaEhCNUVSclhyTkhodXBGaVQzRmRkWjk3alZYQW82akFWQi1oMWdxSXVWT2hYWUFOb3l5OFlWN2NNWDBmNmc5VnlSYXk5WURLVE9aTm1hZjhGbkRKdk41d2FrTHY5cWVVY0RFVUVPbS1LZ2JjMU03RjNVMmZEU3FwRFdhd2tSOFpLUi1ZWHFoUGVHWkR2VWZaTjg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNbUxaVGpOTU5oZFZxeXc2OVRUNEhMdElKNmJ1V2YyNWY0RVVqNWk5LTRhVVpBekNjMVl0R01QZG5kNDdId1FvWW5xaEhCNUVSclhyTkhodXBGaVQzRmRkWjk3alZYQW82akFWQi1oMWdxSXVWT2hYWUFOb3l5OFlWN2NNWDBmNmc5VnlSYXk5WURLVE9aTm1hZjhGbkRKdk41d2FrTHY5cWVVY0RFVUVPbS1LZ2JjMU03RjNVMmZEU3FwRFdhd2tSOFpLUi1ZWHFoUGVHWkR2VWZaTjg?oc=5", "title": "Saratoga Research & Investment Management Sells 200,320 Shares of Novo Nordisk A/S $NVO", "content_text": "Saratoga Research & Investment Management Sells 200,320 Shares of Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:19:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:d40ad7328e447738b00d9f8d2159060f6a7d5d95c9f0ce102423e5ef35886830", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNRUZTSTM4YnBCVHo5dEVPY3lzYVo1M29wbmZsd0NUYTRjMVBmeEpvQ3U3R1BfczdvdkdaSmVVMl9ES1lha1FWSGgzb2hOZDZTRDBfTldMMk5KV0xSNWRybDg1SXJQajZKWUl6LXpXRDBHaXBGWWdLMm9JTDhJcmpoXzlkaGowSExtU0NQNzdiUDh1bl9Sby1ueHdVVkNyUWgwUFBvcUpWTFUzYk1lenR2QzdVbUxGdk9tUEY5RXgyMWxGMlU0UzFHOEltSmg4eXQ3R25MMkRLSEI?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNRUZTSTM4YnBCVHo5dEVPY3lzYVo1M29wbmZsd0NUYTRjMVBmeEpvQ3U3R1BfczdvdkdaSmVVMl9ES1lha1FWSGgzb2hOZDZTRDBfTldMMk5KV0xSNWRybDg1SXJQajZKWUl6LXpXRDBHaXBGWWdLMm9JTDhJcmpoXzlkaGowSExtU0NQNzdiUDh1bl9Sby1ueHdVVkNyUWgwUFBvcUpWTFUzYk1lenR2QzdVbUxGdk9tUEY5RXgyMWxGMlU0UzFHOEltSmg4eXQ3R25MMkRLSEI?oc=5", "title": "Merit Financial Group LLC Has $53.25 Million Stock Position in Johnson & Johnson $JNJ", "content_text": "Merit Financial Group LLC Has $53.25 Million Stock Position in Johnson & Johnson $JNJ", "date_published": "2026-08-14T10:19:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:ade001452edbf036d90da41d876ca5bb63cb3732a97ce55767440431e3ebb200", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPbjVjRGU0TTVSQ2ZIcThzRFA1UVdkUHN4ZGRYNzZPVHZ6akJBM1FnUFdTWlo4MXdiYVp0S3d5OEtid1FnR2NIMm9oRE5kRjdSM0FMaFlBd1R5dV9vYi1JUURuVW92YTJjTmZYREY1R0ZDR09nT3A1Qy1wYml2dU1kVEsxVU9JcGc2V3ZkSnA3QkFPbVVTcG1fZV9rRk42SjUwLXZueThmWlFfSGNrTFdlOEkxSklnN1A5VXM1UTRmRjVCd0pvTkY2NzMweVRNSkNYN0lXRGhtSQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPbjVjRGU0TTVSQ2ZIcThzRFA1UVdkUHN4ZGRYNzZPVHZ6akJBM1FnUFdTWlo4MXdiYVp0S3d5OEtid1FnR2NIMm9oRE5kRjdSM0FMaFlBd1R5dV9vYi1JUURuVW92YTJjTmZYREY1R0ZDR09nT3A1Qy1wYml2dU1kVEsxVU9JcGc2V3ZkSnA3QkFPbVVTcG1fZV9rRk42SjUwLXZueThmWlFfSGNrTFdlOEkxSklnN1A5VXM1UTRmRjVCd0pvTkY2NzMweVRNSkNYN0lXRGhtSQ?oc=5", "title": "Johnson & Johnson $JNJ Stock Holdings Decreased by Gateway Investment Advisers LLC", "content_text": "Johnson & Johnson $JNJ Stock Holdings Decreased by Gateway Investment Advisers LLC", "date_published": "2026-08-14T10:19:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:a5b894bbb17dde7522ff31e80d46acc8da16167c23fec3bd80b43db10bed098e", "url": "https://www.marketbeat.com/instant-alerts/filing-monument-capital-management-decreases-stake-in-gilead-sciences-inc-gild-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-monument-capital-management-decreases-stake-in-gilead-sciences-inc-gild-2026-08-14", "title": "Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD", "content_text": "Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a \"Moderate Buy\" consensus with an average price target of $158.04. Gilead also reported strong quarterly earnings and declared a dividend of $0.82 per share.", "date_published": "2026-08-14T10:18:10+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:db2aafec172f151dbbe74780c6349d009dd3eea1a998bbfc2c3f90bdb3f325cd", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdDRmaUJDZVFQVFZpaFU1NHF2VG5zUHZKT0s1OTdHNE5HejRhc3VoQnF3NTVndG9jcl9oOHBLNFo1WmtCNW1KZUhWY21Cc0VKUm93UzZMb2hlRWt0QzVJYTFKejNsRlFEUFdTY29xUF9iWEZyVndFeWhUbUI2dXRaQ1FMeUdLUHBDQVBsUExkMTFzc0g1Y2pRZ3g4Z0xyVS1lTl9LTTVvWUhYWnVqYVpfLXRJalNIbE1oODItUF9QaF8wdm9lRkpFXzg2WnlBdXlmVWRV?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdDRmaUJDZVFQVFZpaFU1NHF2VG5zUHZKT0s1OTdHNE5HejRhc3VoQnF3NTVndG9jcl9oOHBLNFo1WmtCNW1KZUhWY21Cc0VKUm93UzZMb2hlRWt0QzVJYTFKejNsRlFEUFdTY29xUF9iWEZyVndFeWhUbUI2dXRaQ1FMeUdLUHBDQVBsUExkMTFzc0g1Y2pRZ3g4Z0xyVS1lTl9LTTVvWUhYWnVqYVpfLXRJalNIbE1oODItUF9QaF8wdm9lRkpFXzg2WnlBdXlmVWRV?oc=5", "title": "Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO", "content_text": "Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:17:44+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Deals and strategy", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:b7359b11cf1c82e265c7ba9a78174524918e023614d3696e8731450342705533", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNDgwdXdkU01vaC1mOGtHSGY4a2txOW9vYXk3bFowSlVWRVhhRk9ZbVNFTWJhZVBLS2dVbXoyYmxONi1iWkZ5Uk5KblY3ZTFLRy16TVpsaXlXS2NGOG9Pb3VYMDBHQlZXU2V4NU54N1gwZjBSd1RHeFFFeUxqZVdLVFhUUmpqa0NiOTNrLTlaRU5Eb0F2ZkdURUJiSFF1bkdxVUNVLUw1V09sNnE2NzVjYVljaDVzVHZQYm9fOUtKOUN3M1B0bVp0ZUh1Q0U?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNDgwdXdkU01vaC1mOGtHSGY4a2txOW9vYXk3bFowSlVWRVhhRk9ZbVNFTWJhZVBLS2dVbXoyYmxONi1iWkZ5Uk5KblY3ZTFLRy16TVpsaXlXS2NGOG9Pb3VYMDBHQlZXU2V4NU54N1gwZjBSd1RHeFFFeUxqZVdLVFhUUmpqa0NiOTNrLTlaRU5Eb0F2ZkdURUJiSFF1bkdxVUNVLUw1V09sNnE2NzVjYVljaDVzVHZQYm9fOUtKOUN3M1B0bVp0ZUh1Q0U?oc=5", "title": "17,243 Shares in Johnson & Johnson $JNJ Bought by Thomasville National Bank", "content_text": "17,243 Shares in Johnson & Johnson $JNJ Bought by Thomasville National Bank", "date_published": "2026-08-14T10:12:43+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:abc1eae958c35109bfbcbe2674d0546f19c5f5ba61860997f67e4438ccac40f4", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWNnU1NZR1F5OVQ4MThMdWtSb3FSSUduNFZma0lEb2x1cHcyNHBqQ3hYZzk1cHh1THVQUFlCOGlIVlNBaTRyTGZZWUlDR21WTGQ0aFBpMHNFUDhEaHY4QjR6ZGhHSUpRVFJBbTRNUGVnaE1reDV3NHN2YXgwTUxmNzJXdzhFc216TzRiREdBRmdlZE82eHZhZ1M0WFlNNC0zQ2pjOTlQdjhwMngzaFI4eS1Oc05raExJRzUxdW1QWQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWNnU1NZR1F5OVQ4MThMdWtSb3FSSUduNFZma0lEb2x1cHcyNHBqQ3hYZzk1cHh1THVQUFlCOGlIVlNBaTRyTGZZWUlDR21WTGQ0aFBpMHNFUDhEaHY4QjR6ZGhHSUpRVFJBbTRNUGVnaE1reDV3NHN2YXgwTUxmNzJXdzhFc216TzRiREdBRmdlZE82eHZhZ1M0WFlNNC0zQ2pjOTlQdjhwMngzaFI4eS1Oc05raExJRzUxdW1QWQ?oc=5", "title": "QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO", "content_text": "QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:01:30+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:5cadd270050a862f51b65048349581ab91089de3aac765544f5bf170a07ff2ac", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNR1lHUi1HWnpHUFRjZU90ZEhZX2dHNXpPX1ZjQktvZ01qZWdyejh2ZTVBWEhwVDJucy12eEJkYlhkYnEwYWRub2xaOGVVV0U5SXJxa2JxQ0JpZFdxdHN1ZExkNkcza2QzVHFQMmZ0V1pTTVRsb0VicGRDcGxjNDlrd0Vldk1rYVpCQy1GMW84UmtPRU1tN2tCVUlyZnJ6cWZ2SFhXZUxpaVp2NkpFSjVWcFI0TEZQWnJYSlpldW5lZ3dZWWtQb2ppb1ln?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNR1lHUi1HWnpHUFRjZU90ZEhZX2dHNXpPX1ZjQktvZ01qZWdyejh2ZTVBWEhwVDJucy12eEJkYlhkYnEwYWRub2xaOGVVV0U5SXJxa2JxQ0JpZFdxdHN1ZExkNkcza2QzVHFQMmZ0V1pTTVRsb0VicGRDcGxjNDlrd0Vldk1rYVpCQy1GMW84UmtPRU1tN2tCVUlyZnJ6cWZ2SFhXZUxpaVp2NkpFSjVWcFI0TEZQWnJYSlpldW5lZ3dZWWtQb2ppb1ln?oc=5", "title": "Johnson & Johnson $JNJ Shares Bought by Interchange Capital Partners LLC", "content_text": "Johnson & Johnson $JNJ Shares Bought by Interchange Capital Partners LLC", "date_published": "2026-08-14T10:01:30+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:93d2c495d7c8b26f9cf1a13dc2803c9c9373e38139a22f7fd2fc0e7c257d634f", "url": "https://pmlive.com/pharma_news/bristol-myers-squibb-announces-new-2-3bn-campus-in-the-us", "external_url": "https://pmlive.com/pharma_news/bristol-myers-squibb-announces-new-2-3bn-campus-in-the-us", "title": "Bristol Myers Squibb announces new $2.3bn campus in the US", "content_text": "Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design and multi-modal capabilities will allow for flexible manufacturing of various medicine types, supporting the company's current and future pipeline.", "date_published": "2026-08-14T09:50:19+00:00", "authors": [{"name": "PMLiVE"}], "tags": ["Market update", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:450dc947e40ad299106b8d24bed786edf3855098c847dbef9917bbe56621584d", "url": "https://www.marketbeat.com/instant-alerts/filing-confluence-wealth-services-inc-acquires-7986-shares-of-gilead-sciences-inc-gild-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-confluence-wealth-services-inc-acquires-7986-shares-of-gilead-sciences-inc-gild-2026-08-14", "title": "Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILD", "content_text": "Confluence Wealth Services Inc. significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 251.4% during the second quarter, acquiring an additional 7,986 shares, bringing its total holdings to 11,162 shares valued at $1.41 million. Gilead reported strong Q2 revenue of $7.80 billion, exceeding analyst expectations, driven by its Biktarvy and HIV prevention franchises. The company also declared a quarterly dividend of $0.82 per share and maintains a \"Moderate Buy\" consensus rating from analysts, despite mixed revisions to earnings estimates.", "date_published": "2026-08-14T08:19:17+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:9f01b547b8dfdce2063a66979fd8af13d271a5129d034f2535aa445e58cb4f11", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPRUJxVTFhS3MwaW1PRVFWZy1yUDFtYjgxVTc4dkUxT1F1U0lSMGItcHNwWjRJekNSNUo1cDl1a2JaLTBSei1rcGNueE85VVpMamNzODZkaU04UWJiZlYwVUNjOTBWTHhHblZMdmhoQndoVElGbzFOZHFYbkhHa1VjaXd1REdiZllpNUhHNEhVRmwwbkZWQklMcS1QcEd4My14djRxai1PSXFTZ2JKZmdxbHpKS3k4MWhaNGV5cnhDQUJjOEs3U0JvNHQ1bXo?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPRUJxVTFhS3MwaW1PRVFWZy1yUDFtYjgxVTc4dkUxT1F1U0lSMGItcHNwWjRJekNSNUo1cDl1a2JaLTBSei1rcGNueE85VVpMamNzODZkaU04UWJiZlYwVUNjOTBWTHhHblZMdmhoQndoVElGbzFOZHFYbkhHa1VjaXd1REdiZllpNUhHNEhVRmwwbkZWQklMcS1QcEd4My14djRxai1PSXFTZ2JKZmdxbHpKS3k4MWhaNGV5cnhDQUJjOEs3U0JvNHQ1bXo?oc=5", "title": "Exchange Traded Concepts LLC Cuts Stock Holdings in Novo Nordisk A/S $NVO", "content_text": "Exchange Traded Concepts LLC Cuts Stock Holdings in Novo Nordisk A/S $NVO", "date_published": "2026-08-14T08:13:51+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:e1a480fcd3d2c868cff045f7ecca5b1125b382b7b0ee1b2b66038c916704c336", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQODloZkFGMzRvbGc4RFk2NmxUMDczMXN2VU1HMTFBQ3ZhRUVTUjNHMkVET29zUUpsUDR1cWlIS2NiV1RSSm1zdzIzalRVZjJiRUNQQ0hvN21VekJydzhnWjBIMHEyNkFkQ3hPamxuSkp1cWYzaFdyQVhscERlZ3Y4MFUyY01uVUk4ZGdWZ1NaVWdRUGVkOUo5Yzk3RUFnSGxWNUo2UE1laWEybVRPQTN6OWk4UHd0ajk0bFdvdkRQUHFPaHhyU1lRS0dpaUIxMjd5TkRLR3NR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQODloZkFGMzRvbGc4RFk2NmxUMDczMXN2VU1HMTFBQ3ZhRUVTUjNHMkVET29zUUpsUDR1cWlIS2NiV1RSSm1zdzIzalRVZjJiRUNQQ0hvN21VekJydzhnWjBIMHEyNkFkQ3hPamxuSkp1cWYzaFdyQVhscERlZ3Y4MFUyY01uVUk4ZGdWZ1NaVWdRUGVkOUo5Yzk3RUFnSGxWNUo2UE1laWEybVRPQTN6OWk4UHd0ajk0bFdvdkRQUHFPaHhyU1lRS0dpaUIxMjd5TkRLR3NR?oc=5", "title": "Gilead Sciences, Inc. $GILD Stock Position Lifted by Exchange Traded Concepts LLC", "content_text": "Gilead Sciences, Inc. $GILD Stock Position Lifted by Exchange Traded Concepts LLC", "date_published": "2026-08-14T08:11:00+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:cafe33c7ee73f6b984147b313061d92fcd1333eadfcaa3189464866c61cca1ba", "url": "https://finance.yahoo.com/markets/stocks/articles/5-revealing-analyst-questions-eli-054900384.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/5-revealing-analyst-questions-eli-054900384.html", "title": "5 Revealing Analyst Questions From Eli Lilly\u2019s Q2 Earnings Call", "content_text": "5 Revealing Analyst Questions From Eli Lilly's Q2 Earnings Call Eli Lilly's second quarter was marked by a positive market reaction, despite the company missing Wall Street's revenue expectations. Management credited growth in key products\u2014especially in cardiometabolic health, oncology, and neuroscience\u2014as drivers of performance. CEO David Ricks pointed to \"robust revenue growth across all Key Products and major geographies,\" noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing investments in manufacturing and R&", "date_published": "2026-08-14T05:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}]}}, {"id": "source:55fb9d3b367caafaef649731e41e3e7086a463edc8be607b34dcbd26ad3d6f90", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQUW9lUjE1dEdBREFKYkpZVXpFYlJOOU9SU0ZRMFhacmd3c3JHSzNyMGNHOHA1Rm5leVVlTW53MHc4WHR5LTRaT1hmanpKSG1JRzFaZmd2M1BVTDlPVERqa0tfeVBQVl84YXlrZE1rM2JEQXpXX282ak9GdEplMERlOGtqTXktSFRYN1B3VEFvbVhQOHpwMjlzMHB4Ulo1djNkTDk4WDF3Zk5IN3Q1ZUFWSmZFT2s2Zw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQUW9lUjE1dEdBREFKYkpZVXpFYlJOOU9SU0ZRMFhacmd3c3JHSzNyMGNHOHA1Rm5leVVlTW53MHc4WHR5LTRaT1hmanpKSG1JRzFaZmd2M1BVTDlPVERqa0tfeVBQVl84YXlrZE1rM2JEQXpXX282ak9GdEplMERlOGtqTXktSFRYN1B3VEFvbVhQOHpwMjlzMHB4Ulo1djNkTDk4WDF3Zk5IN3Q1ZUFWSmZFT2s2Zw?oc=5", "title": "AstraZeneca stock holds near $157 after earnings beat", "content_text": "AstraZeneca stock holds near $157 after earnings beat", "date_published": "2026-08-14T05:04:33+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Earnings", "AZN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/621fe7b6-7088-42ee-8897-c0a44458e7b3/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc", "sentiment_url": "https://sharemaestro.com/sentiment/932d750f-7374-4126-b519-14313f9c835e/"}]}}, {"id": "source:25e34a0f8f0fe7dc0a40fa9549bf47774fbb1e3a23582683ff24bf4b7fc51435", "url": "https://www.tradingview.com/news/stockstory:4fbeaa426094b:0-gilead-sciences-gild-buy-sell-or-hold-post-q2-earnings", "external_url": "https://www.tradingview.com/news/stockstory:4fbeaa426094b:0-gilead-sciences-gild-buy-sell-or-hold-post-q2-earnings", "title": "Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?", "content_text": "Gilead Sciences (GILD) shares have dropped 11.3% in the last six months, significantly underperforming the S&P 500. The article expresses low confidence in GILD due to disappointing long-term revenue growth (2.7% CAGR over five years), a shrinking adjusted operating margin (down 34.2 percentage points over five years), and declining EPS (15.4% annually over five years). Despite a fair valuation at 14.9x forward P/E, the upside potential is deemed low compared to the downside risks.", "date_published": "2026-08-14T04:08:10+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:73f203305b5d54485de2deb2823ca9b04af33338a782dd1b173d26623ce497c7", "url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "external_url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "title": "Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?", "content_text": "Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and other negatives, it makes sense why Wall Street isn't liking these merger rumors.10 stocks we like better than Bristol Myers Squibb \u203a In recent weeks, two pharmaceutical stocks, AstraZeneca(NYSE: AZN) and Bristol Myers Squibb(NYSE: BMY), have become the subject of merger rumors. At the start of the m", "date_published": "2026-08-14T02:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "AZN", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/621fe7b6-7088-42ee-8897-c0a44458e7b3/"}, {"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc", "sentiment_url": "https://sharemaestro.com/sentiment/9a54a5f7-3445-44e1-a263-af644888772e/"}]}}, {"id": "source:bf08239040594beca235b813c3b1bef77acd8c19189c256e1aef373793cbbe1f", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-merck-co-inc-nysemrk-evp-sells-10000-shares-of-stock-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/insider-selling-merck-co-inc-nysemrk-evp-sells-10000-shares-of-stock-2026-08-13", "title": "Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells 10,000 Shares of Stock", "content_text": "Merck & Co., Inc. EVP Chirfi Guindo recently sold 10,000 shares of the company's stock for $1.35 million, reducing his direct ownership by over 21%. This sale occurred as MRK shares traded near a 52-week high and the company reported strong quarterly revenues that exceeded expectations. Analysts currently rate Merck as a \"Moderate Buy\" with an average price target of $135.50, and the company also announced a quarterly dividend of $0.85 per share.", "date_published": "2026-08-13T23:19:49+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:43fb835313f01faeda6bcafaf7ebbaf8394c86b41d24f6a7ca130156aae1ed4f", "url": "https://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html", "title": "Could GSK plc (GSK)\u2019s Pipeline Acceleration Unlock a New Growth Era?", "content_text": "On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached \u00a38.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to \u00a32.80 billion and Core EPS rose 9% CER to 50.5p. Growth was primarily fueled by double-digit gains in Specialty Medicines (+14% CER to \u00a33.8 billion) and robust momentum in Vaccines (+8% CER to \u00a32.3 billion). However, Total operating profit dropped 75% CER to \u00a3481 ", "date_published": "2026-08-13T22:01:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GSK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GSK", "name": "GlaxoSmithKline PLC ADR", "sentiment_url": "https://sharemaestro.com/sentiment/6bdf4718-47f6-4d60-8418-df34655523a9/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}, {"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://news.bms.com/news/corporate-financial/2026/U-S--FDA-Grants-Accelerated-Approval-to-Bristol-Myers-Squibbs-First-CELMoD-Therapy-ZENBEXUS-in-Combination-with-Daratumumab-and-Hyaluronidase-fihj-and-Dexamethasone-ZDd-for-Patients-with-Multiple-Myeloma-as-Early-as-First-Relapse/default.aspx", "external_url": "https://news.bms.com/news/corporate-financial/2026/U-S--FDA-Grants-Accelerated-Approval-to-Bristol-Myers-Squibbs-First-CELMoD-Therapy-ZENBEXUS-in-Combination-with-Daratumumab-and-Hyaluronidase-fihj-and-Dexamethasone-ZDd-for-Patients-with-Multiple-Myeloma-as-Early-as-First-Relapse/default.aspx", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval for ZENBEXUS\u2122 (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy. This approval, based on the EXCALIBER-RRMM trial, marks the first FDA-approved CELMoD therapy and is significant as it's the first approval in relapsed or refractory multiple myeloma based on minimal residual disease (MRD)-negative complete response. The company emphasizes the importance of this new treatment class in expanding options for patients with multiple myeloma, noting the safety profile and the potential for continued clinical benefit to be verified in confirmatory trials.", "date_published": "2026-08-13T21:37:15+00:00", "authors": [{"name": "Bristol Myers Squibb"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://uk.finance.yahoo.com/news/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://uk.finance.yahoo.com/news/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. reported strong first-quarter 2026 financial results with significant revenue growth driven by Skyrizi and Rinvoq, and raised its full-year EPS guidance. The company also secured European approval for Boey, expanding its aesthetic portfolio. Analysts remain largely positive, though concerns about elevated debt and Humira's revenue decline persist, with institutional investors showing increasing confidence in AbbVie's strategic execution.", "date_published": "2026-08-13T21:33:00+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc", "sentiment_url": "https://sharemaestro.com/sentiment/9a54a5f7-3445-44e1-a263-af644888772e/"}]}}, {"id": "source:a7995484a9a22e8680796521e099825b09c08a479ffd03afa8b7ecd4527864d0", "url": "https://www.stocktitan.net/sec-filings/MRK/form-4-merck-co-inc-insider-trading-activity-55fb90d1aa8e.html", "external_url": "https://www.stocktitan.net/sec-filings/MRK/form-4-merck-co-inc-insider-trading-activity-55fb90d1aa8e.html", "title": "Merck & Co. (MRK) EVP Chirfi Guindo sells 10,000 common shares", "content_text": "Chirfi Guindo, EVP, Access, Policy & Comms at Merck & Co., Inc. (MRK), sold 10,000 shares of common stock on August 13, 2026, at a price of $135.00 per share. This open market transaction reduced his direct holdings to 36,613.127 shares. The sale, valued at $1.35 million, was reported in a Form 4 SEC filing.", "date_published": "2026-08-13T21:08:27+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "MRK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}]}}, {"id": "source:22087c734ca651ad1a45d58f87fda60ebb2b5fde2468e78f18a7f12f67f17c8e", "url": "https://www.marketbeat.com/instant-alerts/merck-co-inc-nysemrk-reaches-new-12-month-high-following-analyst-upgrade-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/merck-co-inc-nysemrk-reaches-new-12-month-high-following-analyst-upgrade-2026-08-13", "title": "Merck & Co., Inc. (NYSE:MRK) Reaches New 12-Month High Following Analyst Upgrade", "content_text": "Merck & Co., Inc. (MRK) stock reached a new 52-week high after Daiwa Securities upgraded it to \"outperform\" with a $143 price target. The company reported strong Q2 revenue of $16.61 billion, exceeding analyst estimates, driven by Keytruda and other oncology products. Despite recent insider stock sales totaling over $4.3 million, analysts maintain a \"Moderate Buy\" rating, although concerns about Keytruda's patent expiration persist.", "date_published": "2026-08-13T20:45:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}]}}, {"id": "source:de4e383cf546960dc486d05be04e287d66fda6d35419699b5a49f83942eadb4e", "url": "https://www.reuters.com/legal/litigation/us-fda-approves-bristol-myers-blood-cancer-treatment-2026-08-13", "external_url": "https://www.reuters.com/legal/litigation/us-fda-approves-bristol-myers-blood-cancer-treatment-2026-08-13", "title": "US FDA approves Bristol Myers' blood cancer treatment", "content_text": "The U.S. FDA has approved Bristol Myers Squibb's combination treatment, iberdomide, for patients with a rare form of blood cancer called multiple myeloma. This treatment is intended for patients whose illness has relapsed or not responded to other therapies. Iberdomide works by targeting the cereblon protein, offering a more effective approach than older treatments.", "date_published": "2026-08-13T20:29:17+00:00", "authors": [{"name": "Reuters"}], "tags": ["Market update", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:720460cd488b418425a9f3ea6bff0f775c5cdce2e561ce04989856d1005e613b", "url": "https://www.stocktitan.net/sec-filings/MRK/form-4-merck-co-inc-insider-trading-activity-9b90ef5bde54.html", "external_url": "https://www.stocktitan.net/sec-filings/MRK/form-4-merck-co-inc-insider-trading-activity-9b90ef5bde54.html", "title": "Merck (MRK) EVP Jennifer Zachary exercises options and sells 80,315 shares", "content_text": "Merck's EVP and General Counsel, Jennifer Zachary, exercised stock options for a total of 54,927 shares and subsequently sold 80,315 common shares on August 12, 2026. The shares were sold at a weighted average price of $133.4557, totaling approximately $10.72 million in gross proceeds. These transactions were not reported under a Rule 10b5-1 trading plan.", "date_published": "2026-08-13T20:13:41+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}]}}, {"id": "source:cfc1fc0bca5a9c70d96a34198d97346814887240b0813f070aecfa35cf55b9d3", "url": "https://www.stocktitan.net/news/ASMB/assembly-biosciences-reports-second-quarter-2026-financial-results-xjqg9hdkw6qa.html", "external_url": "https://www.stocktitan.net/news/ASMB/assembly-biosciences-reports-second-quarter-2026-financial-results-xjqg9hdkw6qa.html", "title": "Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due", "content_text": "Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver diseases and chronic HDV, while Gilead progresses GS-1179 for HSV. Collaboration revenue increased, and the net loss narrowed significantly compared to the previous year.", "date_published": "2026-08-13T20:11:30+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:13e3e612d11f3ff617b97542fa66eeef64eda2fdbc12a3586728455ea9292833", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/what-johnson-johnson-jnjs-leadership-shift-and-cancer-drug-p/amp", "external_url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/what-johnson-johnson-jnjs-leadership-shift-and-cancer-drug-p/amp", "title": "What Johnson & Johnson (JNJ)'s Leadership Shift and Cancer Drug Priority Review Mean For Shareholders", "content_text": "Johnson & Johnson (JNJ) recently announced a leadership change in its Innovative Medicine sector with Jennifer Taubert's retirement and Tom Cavanaugh stepping in. This shift, combined with the FDA Priority Review for subcutaneous amivantamab in head and neck cancer, is expected to influence J&J's investment narrative, emphasizing oncology and immunology to offset patent expirations and support raised sales guidance. While talc litigation and biosimilar impacts remain potential overhangs, the company anticipates significant revenue and earnings growth by 2029.", "date_published": "2026-08-13T20:08:27+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Earnings", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}]}}, {"id": "source:d8193701b80d5e8a89de87cb97ec0cd711391ccebb802b771d513e59d7bbc8da", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-looks-fully-191101570.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-looks-fully-191101570.html", "title": "Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck stock has almost doubled investors' money over the past five years, yet there is a clear split between valuation tools. A Discounted Cash Flow (DCF) estimate points to a sizeable gap to intrinsic value, while market based multiples suggest the shares are already pricing in a lot of optimism. Merck has returned 99.7% over five years, which puts recent gains in focus as investors weigh how much future growth is already r", "date_published": "2026-08-13T19:11:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Company Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f6db1008-c56f-44d2-9216-b4268cb66ffa/"}]}}, {"id": "source:c2bcdb33543a059490b24d3f0d4951518a1ed3d69add158e61e97979a879d332", "url": "https://in.investing.com/news/stock-market-news/kevin-hern-sells-stocks-in-organon--co-and-versant-media-group-93CH-5556045", "external_url": "https://in.investing.com/news/stock-market-news/kevin-hern-sells-stocks-in-organon--co-and-versant-media-group-93CH-5556045", "title": "Kevin Hern sells stocks in Organon & Co. and Versant Media Group", "content_text": "Representative Kevin Hern recently sold shares in Organon & Co. (OGN) and Versant Media Group, Inc. (VSNT) on August 5, 2026, with each transaction valued between $1,001 and $15,000. The sales involved stocks held by the Hern Family Revocable Trust and the Hern Family Foundation. While these transactions offer insight into a Congress member's financial activity, they are personal decisions and do not necessarily reflect broader market trends or Hern's views on the companies.", "date_published": "2026-08-13T19:09:13+00:00", "authors": [{"name": "Investing.com India"}], "tags": ["Market update", "OGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OGN", "name": "Organon & Co", "sentiment_url": "https://sharemaestro.com/sentiment/afefb48b-96f0-4909-b412-f6b29c5f5652/"}]}}, {"id": "source:1edb584b32d39b4b3c886091d07e41dda184a58413c333c692be93afc2b0e3e3", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JNJ/pressreleases/3837330/johnson-johnson-has-increased-its-dividend-for-64-consecutive-years-heres-how-much-10000-invested-pays-annually", "external_url": "https://www.theglobeandmail.com/investing/markets/stocks/JNJ/pressreleases/3837330/johnson-johnson-has-increased-its-dividend-for-64-consecutive-years-heres-how-much-10000-invested-pays-annually", "title": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually.", "content_text": "Johnson & Johnson (NYSE: JNJ) has increased its dividend for 64 consecutive years, a streak surpassed by only nine other publicly traded stocks. A $10,000 investment in J&J stock, at approximately $260 per share, would yield about $204 annually given its new annual dividend of $5.36 per share (a 2.07% forward dividend yield). The stock has also demonstrated strong price appreciation, rising 50% over the past 52 weeks and 26% in 2026, outperforming the S&P 500.", "date_published": "2026-08-13T19:08:46+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Capital return", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://ca.finance.yahoo.com/news/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://ca.finance.yahoo.com/news/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "Novo Nordisk's stock slipped by approximately 1% after CEO Mike Doustdar reframed the obesity treatment market, emphasizing that it's not a winner-takes-all scenario against Eli Lilly. Doustdar highlighted Novo's strong position in the oral GLP-1 market with oral Wegovy and suggested that pills could eventually capture half of the overall market, a significant increase from previous estimates. Despite the potential, investors remain skeptical, pricing Novo Nordisk's stock at a substantial discount due to anticipated fierce competition with Lilly.", "date_published": "2026-08-13T18:38:25+00:00", "authors": [{"name": "Yahoo! Finance Canada"}], "tags": ["Earnings", "NVO", "LLY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}]}}, {"id": "source:e46340d17e79968c874982ea904781e973354887c194146e1ec14e217f9d295c", "url": "https://finance.yahoo.com/markets/stocks/articles/telstra-stock-slips-1-billion-183752032.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/telstra-stock-slips-1-billion-183752032.html", "title": "Telstra Stock Slips as A$1 Billion Buyback Meets Profit Miss", "content_text": "This article first appeared on GuruFocus. Telstra Group (TLGPY), Australia's largest telecommunications provider, slipped 0.5% in Thursday's early Australian trading. The market's message was pretty clear: another giant buyback was not enough. Telstra unveiled a fresh A$1 billion repurchase program, but annual attributable profit of A$2.24 billion came in below the A$2.30 billion Visible Alpha consensus cited by Reuters. And this is hardly Telstra's first swing at shrinking the share count. The company only finished a separate A$1.25 billion buyback in June. Warning! GuruFocus has detected 4 W", "date_published": "2026-08-13T18:37:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:eb7bf2b5cda12550bf9730c1e758fcdd7c600f359cb6075d967e1a7aa6238087", "url": "https://www.stocktitan.net/sec-filings/JNJ/144-johnson-johnson-sec-filing-a779d34cc18e.html", "external_url": "https://www.stocktitan.net/sec-filings/JNJ/144-johnson-johnson-sec-filing-a779d34cc18e.html", "title": "Johnson & Johnson (JNJ) insider Duato plans sale of 123,291 shares", "content_text": "Johnson & Johnson insider Joaquin Duato has filed to sell 123,291 shares of common stock through Fidelity Brokerage Services on August 13, 2026. These shares were acquired via stock option exercise for cash. This planned sale follows a previous sale of 48,480 shares on August 5, 2026, which yielded $12,515,010.09.", "date_published": "2026-08-13T18:08:46+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:7a526d9e188b9cb93edb0624272e42331aa214481dc64425a1d7dfc223f90ca9", "url": "https://qz.com/bristol-myers-squibb-lawsuit-celgene-cvr-appeals-court-081326", "external_url": "https://qz.com/bristol-myers-squibb-lawsuit-celgene-cvr-appeals-court-081326", "title": "Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals", "content_text": "A federal appeals court has reinstated a $6.7 billion lawsuit against Bristol Myers Squibb, brought by UMB Bank on behalf of former Celgene shareholders. The suit alleges Bristol Myers deliberately delayed FDA approvals for three drugs, including the cancer therapy Breyanzi, to avoid payouts tied to its 2019 acquisition of Celgene. The court ruled that UMB Bank had proper standing to sue, overturning a lower court's dismissal.", "date_published": "2026-08-13T17:58:24+00:00", "authors": [{"name": "Quartz"}], "tags": ["Deals and strategy", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:5af3d40ae03dbb144fe2ca1b64096eaa8f33eaa0e07ed83c8a94a8d8392c966b", "url": "https://www.gurufocus.com/news/9032411/biib-upgraded-by-wolfe-research-price-target-raised-to-300", "external_url": "https://www.gurufocus.com/news/9032411/biib-upgraded-by-wolfe-research-price-target-raised-to-300", "title": "BIIB Upgraded by Wolfe Research -- Price Target Raised to $300", "content_text": "Wolfe Research has upgraded Biogen (BIIB) to \"Outperform\" and raised its price target to $300.00, reflecting increased confidence in the company's future. Despite this positive sentiment, GuruFocus considers the stock 8.2% overvalued with a GF Value\u2122 of $194.85, and insider activity shows net selling. Investors are advised to approach BIIB with caution due to valuation concerns and moderate growth prospects, despite a solid GF Score\u2122 of 73/100.", "date_published": "2026-08-13T17:52:27+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Analyst action", "BIIB"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIIB", "name": "Biogen Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f715f74c-b258-4cc2-9c0f-00617f889540/"}]}}, {"id": "source:a037eecd9aac32645ee2d0d31d4fd7f24611ea1ba15b64b64008f2e6918df676", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "title": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?", "content_text": "West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above industry levels. WST's growth drivers remain attractive, but the premium multiple leaves less room for operational missteps. WST's HVP Growth Supports the Bull Case HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organic", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}, {"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:d2b8070a7f11de2bcc7d266e2f82a94fb7c534645525c7d5d6d1821803b2ad18", "url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "title": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story", "content_text": "West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters because the guidance increase was supported by broad HVP momentum rather than a single product line. Execution risks remain in West Vantage and the SmartDose transition, but the earnings trajectory improved. WST's Q2 Beat Resets 2026 Expectations Adjusted earnings rose", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}, {"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:26621352c61d0b750159a97231f49826e1b0292e44f87574a0e92362a2850c66", "url": "https://finance.yahoo.com/healthcare/articles/asceniv-help-adma-stock-combat-174700632.html", "external_url": "https://finance.yahoo.com/healthcare/articles/asceniv-help-adma-stock-combat-174700632.html", "title": "Can Asceniv Help ADMA Stock Combat IG Market Challenges?", "content_text": "ADMA Biologics ADMA is a U.S.-based commercial-stage biopharmaceutical company focused on developing, manufacturing and marketing specialty biologics for immunodeficient patients and individuals at risk of certain infectious diseases. The company currently markets three FDA-approved plasma-derived biologics: Asceniv (immune globulin intravenous \u2013 slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); Bivigam (immune globulin intravenous) for the treatment of PI; and NABI-HB (hepatitis B immune globulin) to provide enhanced immunity against the hepatitis B virus. Asceniv w", "date_published": "2026-08-13T17:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GRFS"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GRFS", "name": "Grifols SA ADR", "sentiment_url": "https://sharemaestro.com/sentiment/4f20926e-8b28-49c9-b316-db0b0d55343a/"}]}}, {"id": "source:9d26d0c671e6b52bc88015349553cd3b7d1b648cb07b94a61c041492b2d92917", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "title": "Novo Nordisk Escalates Weight-Loss War With Eli Lilly", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea", "date_published": "2026-08-13T17:32:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "NVO", "LLY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}]}}]}